Aktienanalyse zu CG Oncology Inc (CGON)CGONCG Oncology Inc

CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT). It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES industry).

CG Oncology Inc is not a good buy right now due to significant financial losses and negative technical indicators. The current price is $59.85, with an RSI of 18.48 indicating oversold conditions. The company reported a net income loss of $79,056,000 in Q2 2026, which raises concerns about its profitability and sustainability. The main risk is the ongoing negative earnings trend, with EPS reported at -$0.90, which reflects the company's struggle to achieve profitability amidst rising R&D expenses.